- Designation granted based on positive interim data from ASPIRO clinical trial
- RMAT designation enables closer and more frequent multidisciplinary interaction with FDA and includes all of the benefits of breakthrough therapy designation
- Plan to meet with FDA to gain alignment on AT132 development plan
PR Newswire
SAN FRANCISCO, Aug. 21, 2018